DealsOct 15, 2026, 08:51 AM
Vivos Therapeutics Acquires 11% Stake in SOD Sciences for $12M Preferred Stock
AI Summary
Vivos Therapeutics, Inc. has entered into a definitive agreement to acquire an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SOD's proprietary pseudohypoxia early-warning test. The transaction, valued at $12 million, will be settled through the issuance of Vivos' newly created Series C Convertible Preferred Stock. This deal is expected to increase Vivos' stockholders' equity, potentially aiding in its efforts to regain compliance with Nasdaq listing rules. The agreement also opens doors for collaboration with Cleveland Clinic Weston and a marketing relationship with American Health Associates (AHA).
Key Highlights
- Vivos Therapeutics to acquire 11% stake in SOD Sciences and 50% interest in pseudohypoxia test for $12M in Series C Preferred Stock.
- Transaction expected to increase Vivos' stockholders' equity and aid in regaining Nasdaq compliance.
- Series C Preferred Stock convertible into 80M shares of common stock at $0.15 per share, subject to exchange cap and ownership limits.
- The deal involves no cash consideration.
- Closing is expected on or about October 15, 2026, subject to customary conditions.
- Potential collaboration opportunities with Cleveland Clinic Weston and American Health Associates (AHA) are anticipated.
- Vivos to include a proposal in its proxy statement to approve issuance of common stock upon conversion of Series C Preferred Stock in excess of the exchange cap.
Price Impact
More from VVOS